The Digital Source For China's Tech Innovation Since 2000

Search
Close

Developer of First China-Made Covid Pill Files for Hong Kong IPO

August 5, 2022
Source: caixinglobal.com caixinglobal.com
News Snapshot:
Genuine Biotech , developer of China’s first approved homegrown Covid-19 pill, filed for an initial public offering in Hong Kong to fund commercialization of the treatment and new drug development. Henan province-based Genuine Thursday applied to the Hong Kong stock exchange for a share sale of undisclosed size. Proceeds will be used to produce and commercialize the Azvudine pill for Covid and development of new drugs to combat HIV and blood cancers, the company said.
Go To Original Source →
Tags: Biotech | China | Covid-19 | developer | development | drug | drugs | fund | Henan | HIV | Hong Kong | Hong Kong Stock Exchange | initial public offering | ipo | KONG | made in China | share | stock | stock exchange | technology

Other Related News:

Huge PLA drills around Taiwan really a message to US and allies, say Chinese analysts

August 9, 2022

Apple Might Have To Delay Its New iPhone Thanks To Chinese Crackdown

August 9, 2022

Taiwan could change its crypto trade perspective with the change of the Ministry of Digital Affairs ? ethereum today news bitcoin and crypto altcoins blockchain

August 9, 2022

Apple asks suppliers in Taiwan to label products as made in China-report

August 9, 2022

Taiwan-based Apple supplier challenged by investor over $4 billion cash pile, Financial Times reports

August 9, 2022

Hong Kong Police Publish Details of USDT Fraud Case in Effort to Raise Public Awareness of Crypto Scams ? ethereum today news bitcoin and crypto altcoins blockchain

August 9, 2022

Apple Might Have To Delay Its New iPhone Thanks To Chinese Crackdown

August 9, 2022

Chinese companies may have to exit sub-Rs 10,000 mobile market Business Standard News

August 9, 2022

Apple yields to China’s pressure and labels Taiwan products as “Made in China”

August 9, 2022
  • Contact Us
  • About Us
  • Corrections and Disclosure
  • Privacy Policy
  • Terms & Conditions
Menu
  • Contact Us
  • About Us
  • Corrections and Disclosure
  • Privacy Policy
  • Terms & Conditions
© 2022 ChinaTechNews.com. A Service of Asia Media Network.
Twitter
Posting....